Fresenius Medical Care AG (FMS)
| Market Cap | 14.43B |
| Revenue (ttm) | 20.02B |
| Net Income (ttm) | 556.90M |
| Shares Out | 293.41M |
| EPS (ttm) | 1.89 |
| PE Ratio | 25.91 |
| Forward PE | 12.23 |
| Dividend | $0.63 (2.55%) |
| Ex-Dividend Date | May 17, 2024 |
| Volume | 293,179 |
| Open | 24.91 |
| Previous Close | 24.55 |
| Day's Range | 24.77 - 25.11 |
| 52-Week Range | 17.93 - 25.25 |
| Beta | 0.91 |
| Analysts | Hold |
| Price Target | 25.00 (+0.89%) |
| Earnings Date | May 6, 2025 |
About FMS
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient’s residence; and dialysis services under contract to hospitals in the United States for the hospital... [Read more]
Financial Performance
In 2024, Fresenius Medical Care AG's revenue was 19.34 billion, a decrease of -0.61% compared to the previous year's 19.45 billion. Earnings were 537.91 million, an increase of 7.80%.
Financial numbers in EUR Financial StatementsAnalyst Forecast
According to one analyst, the rating for FMS stock is "Hold" and the 12-month stock price forecast is $25.0.
News
Fresenius Medical Care publishes its joint Annual Report and Sustainability Statement for 2024: Building the Momentum
In 2024, the operating model to deliver the highest quality of patient care was further optimized by enhancing financial returns, and creating value for shareholders Fresenius Medical Care delivered 1...
Fresenius Medical Care's stock falls on Fresenius' stake sale
Dialysis firm Fresenius Medical Care shares fell 7.8% after German healthcare group Fresenius SE sold part of its stake in the company.
Fresenius Medical Care AG (FMS) Q4 2024 Earnings Conference Call Transcript
Fresenius Medical Care AG (FMS) Q4 2024 Earnings Conference Call Transcript
Fresenius Medical Care delivers 18% earnings growth in 2024 and continues the acceleration momentum into 2025
Organic revenue growth1 of 4% driven by Care Enablement and Care Delivery Underlying U.S. same market treatment growth further accelerated in Q4 and turned positive for the full year Accumulated savin...
Fresenius Medical Care slightly beats market estimates in fourth quarter
Fresenius Medical Care , the world's largest dialysis specialist, reported fourth quarter results slightly above market expectations on Tuesday, citing positive development both in its care delivery a...
Fresenius Medical Care Announces Divestment of Select Laboratory Assets to Quest Diagnostics
Quest to provide comprehensive dialysis-related laboratory and water testing services to Fresenius Medical Care owned and affiliated clinics in the United States BAD HOMBURG, Germany and SECAUCUS, N.J...
Fresenius Medical Care: A 'Buy' Going Into 2025
Fresenius Medical Care is a leader in global kidney care, showing significant growth and an 18.5% increase since my last article. The company is attractively valued, trading at less than 18.5x P/E, wi...
Fresenius Medical Care Listed in The Dow Jones Sustainability World Index and for the 15th Time in The Dow Jones Sustainability Europe Index
Ranking puts Fresenius Medical Care among the best-in-class sustainability performers in the world and Europe The company recorded progress towards its sustainability targets Sustainability is one of ...
Fresenius Medical Care returns to Dax 40 Index
BAD HOMBURG, Germany , Dec. 20, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for people with kidney disease, will return to the top tier of ...
Hard work paying off despite challenges from U.S. weather-related events: Fresenius Medical Care CEO
Helen Giza, the CEO of Fresenius Medical Care, discusses the German healthcare firm's third-quarter earnings.
Fresenius Medical Care AG (FMS) Q3 2024 Earnings Call Transcript
Fresenius Medical Care AG (NYSE:FMS) Q3 2024 Earnings Conference Call November 5, 2024 8:00 AM ET Company Participants Dominik Heger - Head, Investor Relations Helen Giza - Chief Executive Officer an...
Fresenius Medical Care reports strong operating income margin growth in the third quarter of 2024
Organic revenue growth of +2% supported by Care Enablement and Care Delivery Underlying U.S. dialysis treatment volume growth turns positive Exceeding full year FME25 savings target, with additional E...
Fresenius Medical Care Showcases Research and Innovations in Kidney Care at American Society of Nephrology (ASN) Kidney Week 2024
A dedicated session will highlight new advancements in hemodiafiltration therapy showcasing its potential to improve patient outcomes through enhanced toxin removal in dialysis treatments. Company-wid...
Fresenius Medical Care: Let's Look At The Upside
Fresenius Medical Care is a BBB-rated leader in kidney care with a 3.1% yield, undervalued at 14x P/E, and poised for growth by 2025-2026E. Despite recent earnings declines, the company expects growth...
Fresenius Medical Care Grows Number of U.S. Patients Using Company's Home Hemodialysis Machines, Launches NxStage® Versi®HD with GuideMe Software
Fresenius Medical Care achieves growth milestone of more than 14,000 U.S.-based patients using the Company's NxStage systems to perform Home Hemodialysis therapy This growth has generated greater adop...
Fresenius Medical Care CEO says strategy is working as company delivers on transformation efforts
Fresenius Medical Care CEO Helen Giza comments on the firm's second-quarter earning results.
Fresenius Medical Care AG (FMS) Q2 2024 Earnings Call Transcript
Fresenius Medical Care AG (NYSE:FMS) Q2 2024 Earnings Call July 30, 2024 8:00 AM ET Company Participants Dominik Heger - Head, Investor Relations Helen Giza - Chief Executive Officer and Chair Martin...
Fresenius Medical Care delivers continued operating income improvements in the second quarter of 2024
Organic revenue growth of +2.3% supported by both segments Care Delivery and Care Enablement Operating income1 and operating income margin1 increase driven by Care Enablement Additional FME25 savings ...
US FTC probing DaVita, Fresenius Medical, Politico reports
The U.S. Federal Trade Commission (FTC) is investigating healthcare providers DaVita and Fresenius Medical Care over allegations that the companies have been illegally thwarting smaller competitors, P...
Fresenius Medical Care: Significant Upside Remains
Fresenius Medical Care has underperformed since 2017, declining over 50% in the market. Despite the decline, the company remains a market leader in dialysis services with a strong product line. The co...
Fresenius Medical Care takes next important step towards goal to reduce CO2 emissions in its operations
Fresenius Medical Care enters virtual power purchase agreements for renewable energy to clearly step forward in reducing CO2 emissions footprint Company enacts five virtual power purchase agreements f...
Moody's and S&P change Fresenius Medical Care's rating outlook to stable
The change of the rating outlook reflects the company's progress in restoring credit metrics and the commitment to maintain its investment grade rating FME is expected to maintain its good growth mome...
Fresenius Medical Care showcases leadership and innovation in kidney care disease at 61st European Renal Association (ERA) Congress 2024
Enhancing kidney care through innovative approaches by data-driven insights and real-world evidence Company-wide experts highlight robust anonymized dialysis database CONVINCE study and the remarkable...
Fresenius Medical Care Annual General Meeting: Company makes significant progress in its Transformation Efforts and confirms its ambitious 2024 Growth Targets
Today's Annual General Meeting was the first one following the change in legal form completed in November 2023 Shareholders voted in favor of the proposed dividend of 1.19 euros, representing an incre...
Fresenius Medical sees up to 2% US dialysis growth by year-end
The number of kidney dialysis sessions provided by Fresenius Medical Care in its top market, the United States, could rise by as much as 2% by the end of the year, its CEO said, as the impact of the p...